PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY

被引：0
|
作者：
Shabnaz, S. [1 ]
Williams, R. [1 ]
Rubinstein, S. [2 ]
Fradley, M. [3 ]
Baz, R. [4 ]
Pepine, C. [1 ]
Lenihan, D. [5 ]
Cornell, R. [6 ]
Gong, Y. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Univ N Carolina, Chapel Hill, NC USA
[3] Univ Penn, Philadelphia, PA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] St Francis Med Ctr, Cape Girardeau, MO USA
[6] AbbVie, Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-052
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [1] Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
    Cornell, Robert F.
    Ky, Bonnie
    Weiss, Brendan M.
    Dahm, Cherie N.
    Gupta, Deepak K.
    Du, Liping
    Carver, Joseph R.
    Cohen, Adam D.
    Engelhardt, Brian G.
    Garfall, Alfred L.
    Goodman, Stacey A.
    Harrell, Shelton Lacy
    Kassim, Adetola A.
    Jadhav, Trafina
    Jagasia, Madan
    Moslehi, Javid
    O'Quinn, Rupal
    Savona, Michael R.
    Slosky, David
    Smith, Amanda
    Stadtmauer, Edward A.
    Vogl, Dan T.
    Waxman, Adam
    Lenihan, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (22) : 1946 - +
  • [2] Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
    Cornell, Robert Frank
    Ky, Bonnie
    Weiss, Brendan M.
    Du, Liping
    Carver, Joseph R.
    Cohen, Adam D.
    Engelhardt, Brian G.
    Garfall, Alfred L.
    Goodman, Stacey A.
    Harrell, Shelton Lacy
    Kassim, Adetola A.
    Jadhav, Trafina
    Jagasia, Madan
    Moslehi, Javid
    O'Quinn, Rupal
    Savona, Michael R.
    Slosky, David
    Smith, Amanda
    Stadtmauer, Edward A.
    Vogl, Dan T.
    Innis-Shelton, Racquel
    Waxman, Adam
    Lenihan, Daniel
    BLOOD, 2017, 130
  • [3] MIRNA-125A ASSOCIATION WITH CARFILZOMIB-RELATED CARDIOVASCULAR ADVERSE EVENTS IN MULTIPLE MYELOMA PATIENTS: PROSPECTIVE OBSERVATION OF CARDIAC SAFETY WITH PROTEASOME INHIBITOR (PROTECT) STUDY
    Tantawy, M.
    Langaee, T.
    Wang, D.
    Rubinstein, S.
    Cornell, R.
    Lenihan, D.
    Fradley, M.
    Gong, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S60 - S60
  • [4] Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
    Chen J.H.
    Lenihan D.J.
    Phillips S.E.
    Harrell S.L.
    Cornell R.F.
    Cardio-Oncology, 3 (1)
  • [5] Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)
    Zonder, Jeffrey A.
    Usiinani, Saad
    Scott, Emma C.
    Harneister, Craig C.
    Lendvai, Nikoletta
    Berdeja, Jesus C.
    Anderson, Larry D., Jr.
    Hari, Parameswaran
    Singhal, Seeina
    Orloff, Gregory
    Craig, Michael
    Valent, Jason
    Lee, Wes
    Hart, Lowell
    Hrom, J.
    Tarantolo, Stephano
    Faber, Edward
    Schiller, Gary J.
    Schreiber, Jennifer
    Oliver, Colleen
    Rush, Selena A.
    Tunquist, Brian
    Ptaszynski, Mieke
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [6] Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
    Jagannath, Sundar
    Vij, Ravi
    Kaufman, Jonathan L.
    Martin, Thomas
    Niesvizky, Ruben
    Gabrail, Nashat Y.
    Alsina, Melissa
    Wong, Alvin F.
    Le, Mai H.
    McCulloch, Leanne
    Hannah, Alison L.
    Kauffman, Michael
    Siegel, David Samuel diCapua
    BLOOD, 2010, 116 (21) : 814 - 814
  • [7] Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
    Terpos, Evangelos
    Stamatelopoulos, Kimon
    Makris, Nikolaos
    Georgiopoulos, Georgios
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Laina, Ageliki
    Eleutherakis-Papaiakovou, Evangelos
    Fotiou, Despina
    Kanellias, Nikolaos
    Malandrakis, Panagiotis
    Delialis, Dimitris
    Andreadou, Ioanna
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    CANCERS, 2021, 13 (20)
  • [8] Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
    Singhal, Seema B.
    Siegel, David Samuel diCapua
    Martin, Thomas
    Vij, Ravi
    Wang, Michael
    Jakubowiak, Andrzej J.
    Lonial, Sagar
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Wong, Alvin F.
    McCulloch, Leanne
    Kauffman, Michael
    Badros, Ashraf Z.
    Niesvizky, Ruben
    Orlowski, Robert Z.
    Stewart, A. Keith
    Jagannath, Sundar
    BLOOD, 2010, 116 (21) : 814 - 815
  • [9] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
    Berdeja, Jesus G.
    Gregory, Tara K.
    Matous, Jeffrey
    Hart, Lowell L.
    Owera, Rami
    Mace, Joseph Ronald
    Essell, James H.
    Flinn, Ian
    Faber, Edward Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM).
    Martin, Thomas
    Singhal, Seema B.
    Vij, Ravi
    Wang, Michael
    Keith-Stewart, A.
    Jagannath, Sundar
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Kukreti, Vishal
    Bahlis, Nizar J.
    Alsina, Melissa
    Chanan-Khan, Asher A.
    Somlo, George
    Buadi, Francis
    Reu, Frederic J.
    Zonder, Jeffrey A.
    Song, Kevin
    Stadtmauer, Edward A.
    Wong, Alvin F.
    Vallone, Marcy
    Chang, Yu-Lin
    Kauffman, Michael
    Orlowski, Robert Z.
    Siegel, David Samuel diCapua
    BLOOD, 2010, 116 (21) : 1249 - 1250
12345